Guggenheim Adjusts Price Target on Amgen to $435
Guggenheim maintained its Neutral rating on Amgen while increasing its price target from $378 to $435.
Stocks · News reference
Amgen Raises Full-Year Outlook Following Strong Third-Quarter Results
Amgen reported third-quarter 2026 financial results that exceeded analyst expectations and subsequently raised its full-year revenue and earnings guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435
Amgen Announces Real-World Study Results for Repatha
Amgen reported new real-world study data indicating that its cholesterol-lowering medication Repatha (evolocumab) outperformed ezetimibe in reducing heart disease risk.
Amgen Announces Results From Large Real-World Study Showing Treatment With Repatha Reduced Risk Of Fatal Or Nonfatal Heart Attacks By 20% Compared With Ezetimibe In People With ASCVD And Prior Statin Use
Amgen Price Target Raised by Analyst
An analyst has increased the price target for Amgen Inc. shares to $400.00 from $345.00.
Citigroup Maintains Neutral on Amgen, Raises Price Target to $465